(R)-(4-benzyloxyphenyl)(tert-butoxycarbonylamino)acetic acid methyl ester | 342898-56-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-(4-benzyloxyphenyl)(tert-butoxycarbonylamino)acetic acid methyl ester
• 英文别名: methyl (R)-2-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)acetate；methyl N-tert-butoxycarbonyl-4-(phenylmethoxy)-D-phenylglycinate；methyl (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(4-phenylmethoxyphenyl)acetate
• CAS: 342898-56-0
• 化学式: C₂₁H₂₅NO₅
• 分子量: 371.433
• InChiKey: BHJYLFZXHARKQY-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-(4-benzyloxyphenyl)(tert-butoxycarbonylamino)acetic acid methyl ester 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 4-O-benzyloxy-N-tert-butoxycarbonyl-R-phenylglycine
  参考文献：
  名称：

  [EN] NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS ANTIŒSTROGÈNES HÉTÉROCYCLIQUES

  摘要：

  本发明提供了一种新型杂环化合物，其化学式如下：其中A、B、E、环Z、Y、L、环X、D、m、n、R7和R8如规范中所定义，作为雌激素受体拮抗剂/降解剂。化合物的化学式I可用于治疗由雌激素受体介导的癌症。

  公开号：

  WO2018138739A1
• 作为产物：
  描述：

  溴甲苯 、 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以65 %的产率得到(R)-(4-benzyloxyphenyl)(tert-butoxycarbonylamino)acetic acid methyl ester
  参考文献：
  名称：

  MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

  摘要：

  Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

  公开号：

  WO2023250059A1

文献信息

• Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies
  作者：Claudia Bello、Michele Cea、Giovanna Dal Bello、Anna Garuti、Ilaria Rocco、Gabriella Cirmena、Eva Moran、Aimable Nahimana、Michel A. Duchosal、Floriana Fruscione、Paolo Pronzato、Francesco Grossi、Franco Patrone、Alberto Ballestrero、Marc Dupuis、Bernard Sordat、Alessio Nencioni、Pierre Vogel

  DOI：10.1016/j.bmc.2010.03.009

  日期：2010.5

  Novel alpha-mannosidase inhibitors of the type (2R,3R,4S)-2-([(1R)-2- hydroxy-1-arylethyl]amine}methyl) pyrrolidine-3,4-diol have been prepared and assayed for their anticancer activities. Compound 30 with the aryl group = 4-trifluoromethylbiphenyl inhibits the proliferation of primary cells and cell lines of different origins, irrespective of Bcl-2 expression levels, inducing a G2/Mcell cycle arrest and by modification of genes involved in cell cycle progression and survival. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIŒSTROGÈNES HÉTÉROCYCLIQUES
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2018138739A1

  公开（公告）日：2018-08-02

  The present invention provides novel heterocyclic compounds of Formula I wherein A, B, E, ring Z, Y, L, ring X, D, m, n, R7 and R8 are as defined in the specification as estrogen receptor antagonists/degraders. The compound of Formula I can be used for the treatment of cancers mediated by estrogen receptors. (Formula I ).

  本发明提供了一种新型杂环化合物，其化学式如下：其中A、B、E、环Z、Y、L、环X、D、m、n、R7和R8如规范中所定义，作为雌激素受体拮抗剂/降解剂。化合物的化学式I可用于治疗由雌激素受体介导的癌症。